WIC 2017 Day 3, Thursday 2nd November 2017

08:00 Registration Opens

08:50 Conference doors open

Day 3 plenary session – World leading research


Chair's opening remarks

Sir Gregory Winter

Keynote: Bicycles - a paradigm shift in pharmaceutical drugs?

  • New platform based on repertoire technology
  • Peptide conjugates with toxic drugs for treatment of cancer
Prof. Andreas Plueckthun

Keynote: Future Biologics: Exploiting the opportunities for protein engineering

  • Future biologics need to open areas of application that expand on today’s possibilities. This will be illustrated in several key areas
  • The possibility of engineering geometry can be used to exert extremely strong effects on receptor signalling, such as a pan-HER inhibition
  • Intracellular targets may gradually come within reach. Using systems inspired by engineered bacterial toxins (3), levels can now be reached which are much higher than with positively charged peptides, and more importantly, allow cell-specific uptake
  • Viral delivery may open new avenues to administer cocktails of therapeutic proteins in a localized manner, not by creating replication-proficient “oncolytic” viruses, but instead by engineering viruses, able to target predesigned cell types (5), which can be used to produce therapeutic proteins in vivo, at locations where they are needed

Dr Christoph Rader

Keynote: Cancer therapy with antibodies at the interface of biology and chemistry

  • The presentation will encompass two strategies on covalently combining antibodies with small molecules to improve their scope and potency
  • One strategy employs homogeneous antibody-drug conjugates that selectively deliver highly toxic small molecules to cancer cells without harming healthy cells
  • The other strategy is based on chemically programmed bispecific antibodies that endow cancer-targeting small molecules with the power of cancer immunotherapy
Dr M. Anthony Moody

Keynote: Immune regulation and the antibody response to HIV-1

  • Many antibodies that have potent activity against HIV-1 have characteristics of autoantibodies
  • Infected persons who make those antibodies have Immune system perturbations suggestive of dysregulation
  • Understanding the relationship between immune dysregulation and HIV-1 antibody responses may help guide vaccine design

10:55 Networking Break

Combination Therapy

Chaired by Jose Saro, Senior Translational Medicine Leader, Roche

Dr Christian Klein

Novel T cell bispecific antibodies for combination therapy of cancer

  • Novel T cell bispecific antibody platform
  • Enhancing TCB activity by novel combination therapy approaches
Dr Jose Saro

Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC) with a novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and

  • CEA CD3 TCB (RG7802, RO6958688) is a novel T-cell bispecific antibody targeting CEA on tumour cells and CD3 on T cells
  • In preclinical models, CEA CD3 TCB displays potent anti-tumour activity, leads to increased intra-tumoural T cell infiltration and activation and upregulates PD-1/PD-L1
  • I will present data from two ongoing dose-escalation phase I studies, RO6958688 is given as monotherapy i.v. QW or in combination (QW) with atezolizumab 1200 mg Q3W in adult patients with advanced CEA+ solid tumours
Martina Canestraro

IMCgp100: From development to the clinic

  • ImmTACTM technology platform to generate high-affinity, bi-specific TCR-molecules
  • In vitro pre-clinical package to assess the safety and efficacy profile of ImmTACTM molecules
  • In vitro data of IMCgp100 in combination with immune checkpoint inhibitors

Novel discovery

Dr Karin Jooss

Driving CD8+ T cell responses to mutational neoantigens in tumors – harnessing immunogenic viral vectors

  • DNA damage may cause mutations in tumors that can generate new antigens, known as tumor-specific neo-antigens (TSNAs)
  • Accurate prediction of TSNAs is key to generate potent TSNA specific vaccine approaches
  • Viral vector based vaccine platforms have shown to induce hi-titer, polyfunctional and durable CD4+ and CD8+ T-cell responses in humans
  • The personalized vaccine is delivered in combination with immune checkpoint blockade, to keep TSNA-induced T-cells active in the immunosuppressive tumor microenvironment

Biomarker discovery

Dr Sidath Katugampola

Immune monitoring assays for first in class cancer immunotherapy trials

  • How to select immune assays for first in class agents
  • Case studies of what, how and when
  • Challenges with pharmacodynamic and patient selection assays for cancer immunotherapy agents

13:25 Networking Lunch

Looking towards the future

Chaired by Alain Beck, Senior Director, NBEs Analytical Chemistry, Pierre Fabre, Associate Editor, mAbs

Eric A Hughes

Future directions: oral delivery of biologics

  • State of biologics market today and the quest to transform injectables into pills
  • Historical challenges of delivering biologics orally
  • New advances in oral delivery:  spotlight on Rani Therapeutics
    • Introduction to Rani’s innovative oral delivery platform
    • Rani’s progress to date
    • PK data (Rani vs. subcutaneous injections) 
  • What the future holds:  the impact oral delivery would have on the biologics market
Dr Ulrich Brinkmann

Next generation bispecific antibodies

  • Bispecific Antibodies: from early concepts to drugs
  • 20 years (Coloma & Morrison 1997) of recombinant bsAb concepts - why did it take so long?
  • Diversity of formats - must have or nice to have?
  • BsAb drugs and bsAbs in clinical development
  • What comes next?
Dr Andreas Hougaard Laustsen

Novel snakebite antivenoms based on oligoclonal recombinant antibodies

  • Snakebite - the world’s most neglected tropical disease
  • The use of toxicovenomics (functional venom proteomics) to identify medically relevant snake venom toxins
  • The use of phage display for discovery of human antibodies capable of neutralizing snake toxins
  • Manufacturing perspectives for recombinant antivenoms
Dr Janice Reichert

Antibodies to watch in 2018

  • A new record (14) for recombinant antibody products granted first marketing approvals may be set in 2017. These products, and those that might be granted approvals in 2018, will be identified.  
  • Antibody therapeutics in Phase 3 clinical studies will be discussed, and those likely to move to regulatory review in 2018 will be noted. 
  • New data on antibody therapeutics development metrics, including clinical phase transition and approval success rates, will be presented.

Closing remarks from Terrapinn

16:00 End of Congress

last published: 19/Oct/17 09:45 GMT